Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01686503 · ClinicalTrials.gov registry record · Phase 2
Intradermal Versus Intramuscular Polio Vaccine Booster in HIV-Infected Subjects
A Phase 2 study, sponsored by Eastern Virginia Medical School.
- Completed
- Registry status
- Phase 2
- Development phase
- 231
- Enrollment target
NCT01686503 is a Phase 2 study that has completed, run by Eastern Virginia Medical School. The registered enrollment target is 231 participants.
The verdict
NCT01686503, a Phase 2 study, has completed, sponsored by Eastern Virginia Medical School.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 231 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether a lower dose of inactivated polio vaccine (IPV) injected into the skin (intradermal administration) can work equally well or better than the standard dose injected into the muscle (intramuscular administration). There are more immune cells in the skin than in the muscle, and other vaccines have been shown to require a lower dose when administered intradermally. The study is being done in participants infected with HIV because HIV-infected people are known to respond less well to vaccines than other groups, so it is particularly important to know if IPV might work better in HIV-infected people if administered intradermally. If it is possible to lower the dose of IPV by intradermal administration, this would make inactivated polio vaccine more affordable in the developing countries where it is most needed
Interventions
- DRUG IPOL (Sanofi Pasteur) inactivated polio vaccine booster dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 231 participants |
| Start Date | 2012-09 |
| Est. Completion | 2013-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01686503
The ClinicalTrials.gov registry entry for NCT01686503 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 231 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eastern Virginia Medical School, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IPOL (Sanofi Pasteur) inactivated polio vaccine booster dose is the first listed.
NCT01686503 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01686503 about?
NCT01686503 is a clinical study titled "Intradermal Versus Intramuscular Polio Vaccine Booster in HIV-Infected Subjects". The purpose of this study is to determine whether a lower dose of inactivated polio vaccine (IPV) injected into the skin (intradermal administration) can work equally well or better than the standard dose injected into the muscle (intramuscular administration). There are more immune cells in the ski...
What is the current status of trial NCT01686503?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 231 participants. The study started on 2012-09. Estimated completion is 2013-08.
What interventions are being tested in trial NCT01686503?
The interventions under investigation include: IPOL (Sanofi Pasteur) inactivated polio vaccine booster dose (DRUG).
Who is sponsoring clinical trial NCT01686503?
This trial is sponsored by Eastern Virginia Medical School, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.